Answers are grounded in this paper and cite their sources.
This study suggests that dupilumab is an effective therapy for recalcitrant cirAEs and does not adversely impact mortality. Due to the observed detrimental effects of systemic glucocorticoid therapy, this study suggests the need to shift away from systemic glucocorticoid immunosuppression and toward targeted immune modulators for irAE management, though prospective randomized trials are necessary to investigate this.
No takes yet. Share an insight, caveat, or question.
Khattab et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: